- 1.9k views
CAR T Cells in Cancer Gene Therapy
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
About the Speaker
Dr. Shibichakravarthy Kannan
Consultant Medical Genetics, Apollo Health and Lifestyle Limited, Hyderabad
Dr. Shibichakravarthy Kannan, MBBS, PhD is a Founder & CEO at Theranosis Life Sciences Pvt Ltd. He is a Physician Scientist from Chennai, India - trained in the USA . He has 15 years of clinical & translational research experience including 3 years of Industry experience in the areas - Bioinformatics, Next Generation Sequencing, Scientific communications at Novartis, Drug Discovery & Development, Clinical Genetics & tumor immunotherapy. Dr Kannan’s research focuses on Tumor Immunology & Immunotherapy. He has more than 20 research publications in high impact peer reviewed medical journals. He is Biobanking Expertise – Founded the Lymphoma Tissue Biobank at MD Anderson; replicating this model in Hyderabad & Bangalore, India and Circulating Tumor Cells – developing a platform for performing liquid biopsy of most common solid tumors such as breast, lung, prostate and colorectal cancer.
Upcoming Case Discussions
Nutrition in Pregnancy
Nutrition in pregnancy is crucial for the health of both the mother and the developing baby. A well-balanced diet rich in essential nutrients like folic acid, iron, calcium, and protein supports fetal growth, reduces the risk of birth defects, and strengthens maternal health. Adequate intake of fruits, vegetables, whole grains, and healthy fats ensures a steady supply of vitamins and minerals. Staying hydrated and managing portion sizes helps avoid complications like gestational diabetes and excessive weight gain. Prenatal supplements may be recommended to meet specific nutritional needs. Proper nutrition fosters a healthy pregnancy and sets the foundation for the baby’s long-term well-being.
Treatment of Renal Disease in ANCA Vasculitis
The treatment of renal disease in ANCA-associated vasculitis (AAV) typically involves a combination of immunosuppressive therapies to control inflammation and prevent further kidney damage. First-line treatment often includes high-dose corticosteroids and cyclophosphamide or rituximab, both of which help to induce remission by targeting the underlying immune system dysfunction. In cases of kidney failure or rapidly progressive glomerulonephritis, plasmapheresis may be used to remove circulating autoantibodies. Once remission is achieved, maintenance therapy with lower doses of immunosuppressants, such as azathioprine or mycophenolate mofetil, is used to prevent relapses and preserve kidney function.
Management of Pulmonary Embolism
Management of pulmonary embolism (PE) involves rapid diagnosis through imaging techniques like CT pulmonary angiography and the administration of anticoagulant therapy to prevent further clot formation. In severe cases, thrombolytic therapy or surgical intervention may be necessary to remove the embolus and restore normal blood flow.
Pulmonary Tuberculosis: Challenges in Diagnosis
Diagnosing pulmonary tuberculosis (TB) poses significant challenges, particularly in resource-limited settings. The disease often mimics other respiratory conditions, leading to delayed or missed diagnoses. Traditional diagnostic methods like sputum smear microscopy have limited sensitivity, especially in HIV co-infected or low-bacterial-load patients. Advanced techniques such as GeneXpert and culture tests, though more accurate, are often unavailable in remote areas. Children and immunocompromised patients present additional hurdles due to atypical symptoms and difficulty obtaining diagnostic samples. Non-specific imaging findings further complicate diagnosis. Addressing these challenges requires expanded access to molecular diagnostics, improved point-of-care tools, and greater healthcare awareness.
NIV in Acute Respiratory Failure
Dr Viny Kantroo is a Chest, Critical Care & Sleep medicine specialist based in Delhi, boasting over more than 15 years of professional experience. She is currently practising as a full time Senior consultant in Indraprastha Apollo Hospitals New Delhi and Visiting Consultant Apollo Hospitals Noida in the department of Respiratory, Critical Care and Sleep Medicine. She is recognised for her expertise in various aspects of Chest medicine, which includes EBUS (Convex probe, Radial), Bronchoscopic procedures, pleural effusion management, interstitial lung disease, Covid-19, lung cancer, pneumonia, and intensive care patient management. Dr Kantroo is renowned not only for her medical proficiency but also for her empathy and positive attitude towards patient care. Patients consulting with Dr Viny can be assured of receiving an accurate diagnosis and effective treatment, thanks to her commitment to prompt and comprehensive care.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Shibichakravarthy Kannan's Talks on Assimilate
- 12th -Nov -2024, TIME : 3:00PM TO 4:00 PM
- 0
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
- 12th -Nov -2024, TIME : 3:00PM TO 4:00 PM
- 0
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
- 12th -Nov -2024, TIME : 3:00PM TO 4:00 PM
- 0
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.
- 12th -Nov -2024, TIME : 3:00PM TO 4:00 PM
- 0
CAR T-cell therapy is a groundbreaking approach in cancer gene therapy that harnesses a patient’s immune cells to target and destroy cancer cells. In this technique, T-cells are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize cancer cells. Once reintroduced into the patient, these CAR T-cells seek out and eliminate cancer cells with high precision. This therapy has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, and is being explored for solid tumors. CAR T-cell therapy offers a promising personalized treatment, with ongoing research aimed at enhancing its safety, effectiveness, and applicability to a wider range of cancers.